BOONTON, N.J., Aug. 5, 2013 /PRNewswire/ -- Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced the official launch of its business, operational and development activities as the Company unveils enhancements to its clinically proven oral peptide delivery platform, Peptelligence™, that extend the technology to small molecule therapeutics. Enteris recently acquired the Peptelligence™ platform, along with proven nasal delivery technology and a recombinant manufacturing process for therapeutically relevant peptides, from Unigene Laboratories, Inc.
In conjunction with the launch of the company and its expansion to oral delivery of small molecules, Enteris has appointed Brian Zietsman as President and Chief Financial Officer, Nozer Mehta, Ph.D., as Chief Scientific Officer and Paul Shields, Ph.D., as its Vice President of Operations.
Mr. Zietsman, Dr. Mehta and Dr. Shields will spearhead Enteris' mission of developing and delivering innovative formulation solutions for peptides and small molecules that leverage the Company's breakthrough delivery platform technologies including Peptelligence™.
Mr. Zietsman commented, "I greatly welcome the opportunity to lead Enteris BioPharma as we seek to become the industry leader in the oral delivery of peptides and difficult to deliver small molecule therapeutics. As a company, we are focused on solving challenging formulation issues for our partners using our proprietary, clinically-proven Peptelligence™ technology in combination with our formulation development and manufacturing expertise. In doing so, we are targeting the myriad therapeutic indications in which physician acceptance and patient compliance can be improved through more convenient and effective medications."
|SOURCE Enteris BioPharma, Inc.|
Copyright©2012 PR Newswire.
All rights reserved